Clinical Trial Update: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a 12-week combination regimen of sofosbuvir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-05-08